Nasal airway obstruction study - NAIROS

Conditions

Deviated septum Ear, Nose and Throat Deviated septum

Homer T, Carrie S, Fouweather T, Teare D, Waugh N, O'Hara J, Wilson JA, Ternent L.

2026-07-06

10.1136/bmjopen-2025-107402

Healthcare professionals’ and patients’ views and experiences of surgical and medical treatment for nasal obstruction: a qualitative interview study for a Nasal Airway Obstruction Study (NAIROS)

Kelly Lloyd, Caroline Wilson, Sean Carrie, Leila Rooshenas, J. A. Wilson et al. (8 authors)

BMJ Open2025-06-011 citations

10.1136/bmjopen-2025-099395

Effectiveness of septoplasty compared to medical management in adults with obstruction associated with a deviated nasal septum: the NAIROS RCT

Sean Carrie, Tony Fouweather, Tara Homer, James O’Hara, Nikki Rousseau et al. (28 authors)

Health Technology Assessment2024-03-0110 citations

10.3310/mvfr4028

Clinical effectiveness of septoplasty versus medical management for nasal airways obstruction: multicentre, open label, randomised controlled trial

Sean Carrie, James O’Hara, Tony Fouweather, Tara Homer, Nikki Rousseau et al. (28 authors)

BMJ2023-10-1819 citations

10.1136/bmj-2023-075445

Interventions

Patients will be randomised to one of two groups in a 1:1 ratio using a variable block stratified design stratified by severity (baseline self-report NOSE category – moderate 30-50

Severe 55-75

extreme 80-100) and gender. Surgery: Participants will undergo septoplasty and turbinate reduction Medical management: Participants receive medical management, which will comprise of regular use of

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Adults aged =18 years with a baseline NOSE score =30 2. Septal Deflection visible at naseondoscopy 3. Capacity to provide informed written consent and complete the study questionnaires.

Exclusion criteria

Exclusion criteria: 1. Patients <18 years 2. Patients with a baseline NOSE score <30 3. Any prior septal surgery 4. Systemic inflammatory disease 5. Granulomatosis with poly angiitis 6. Naseondoscopic evidence of unrelated associated pathology eg. adenoid pad, septal perforation, chronic rhinosinusitis indicated by the prescence of polyposis or pus 7. Intranasal recreational drug use 8. Breastfeeding, pregnancy or intended pregnancy 9. Bleeding diathesis 10. Therapeutic anticoagulation 11. Known adverse reactions to general anaesthesia 12. Immunocompromised patients

Design outcomes

Primary

Measure	Time frame
Patient reported assessment of nasal and general symptoms is assessed using the SNOT 22 questionnaire (Sinonasal Outcome Test) at baseline, 6 and 12 months.	—

Secondary

Measure	Time frame
1. Objective assessment nasal airflow is measured using rhinospirometry (nasal partitioning ratio and peak nasal airflow measurements) at baseline, 6 and 12 months 2. Quality of life is measured using the Short Form 36 Quality of Life Questionnaire at baseline, 6 and 12 months 3. Health utilisation is measured using a health utilisation questionnaire at baseline, 6 and 12 months	—

Countries

England, Scotland, United Kingdom, Wales

Contacts

Public ContactKatherine Rennie

nairos.trial@newcastle.ac.uk+44 (0)191 208 2519

Outcome results

None listed